Spots Global Cancer Trial Database for revlimid
Every month we try and update this database with for revlimid cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma | NCT00799513 | Diffuse Large B... | Lenalidomide | 18 Years - | IRCCS San Raffaele | |
| Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia | NCT00759603 | Chronic Lymphoc... Small Lymphocyt... | Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone | NCT01237249 | Multiple Myelom... | Melphalan Prednisone Velcade Revlimid Dexamethasone | 65 Years - | PETHEMA Foundation | |
| Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL) | NCT03098589 | Lymphoma | Revlimid | 18 Years - | Celgene | |
| VitD3 Supplementation in Patients With Multiple Myeloma | NCT05846880 | Multiple Myelom... | Lenalidomide Vitamin D - Int... Vitamin D - The... | 18 Years - | Augusta University | |
| A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | NCT00424047 | Multiple Myelom... | CC-5013 plus de... Dexamethasone p... | 18 Years - | Celgene | |
| A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea | NCT02556905 | Multiple Myelom... | REVLIMID® Dexamethasone | 18 Years - | Celgene | |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | NCT04739813 | Lymphoma Non-Hodgkin Lym... Diffuse Large B... Burkitt Lymphom... | obinutuzumab prednisone Revlimid Polatuzumab ibrutinib venetoclax | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma | NCT00413036 | Lymphoma, Non-H... | lenalidomide | 18 Years - | Celgene | |
| Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes | NCT00064974 | Myelodysplastic... | CC-5013 | 18 Years - | Celgene | |
| Randomized Trial Comparing Lenalidomide With Low Dose Dexamethasone Versus Lenalidomide in Second Line Multiple Myeloma | NCT01450215 | Multiple Myelom... | Revlimid | 18 Years - | Karolinska University Hospital | |
| Lenalidomide and Paclitaxel in Prostate Cancer | NCT00933426 | Prostate Cancer | Lenalidomide Paclitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma | NCT01729338 | Multiple Myelom... | Velcade Cyclophosphamid... Revlimid | 18 Years - | Duke University | |
| Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) | NCT02279654 | Myelodysplastic... | Lenalidomide | 18 Years - | Celgene | |
| Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma. | NCT00532675 | Multiple Myelom... | LBH589 Lenalidomide | 18 Years - | Novartis | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL) | NCT04618081 | Lymphoma Nonhod... | 18 Years - | Celgene | ||
| CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | NCT00056160 | Multiple Myelom... | CC-5013 Dexamethasone | 18 Years - | Celgene | |
| A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial | NCT00737529 | Mantle Cell Lym... | lenalidomide | 18 Years - | Celgene | |
| A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer | NCT01032291 | Colorectal Canc... | cetuximab lenalidomide | 18 Years - | Celgene | |
| A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma | NCT00478777 | Relapsed or Ref... | Lenalidomide dexamethasone | 18 Years - | Celgene | |
| Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma | NCT01572480 | Multiple Myelom... | Carfilzomib Revlimid Dexamethasone | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | NCT01183663 | Advanced Cancer... | Lenalidomide Bevacizumab Sorafenib Temsirolimus Lenalidomide Oxaliplatin Leucovorin 5-fluorouracil | 18 Years - | M.D. Anderson Cancer Center | |
| Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma | NCT01729338 | Multiple Myelom... | Velcade Cyclophosphamid... Revlimid | 18 Years - | Duke University | |
| Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) | NCT00628238 | Chronic Lymphoc... CLL Untreated Front-line First-Line Initial Therapy | Lenalidomide an... Lenalidomide an... | - | Chronic Lymphocytic Leukemia Research Consortium | |
| Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I | NCT00671801 | Malignant Gliom... | Irinotecan Lenalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT) | NCT01352338 | Multiple Myelom... | Lenalidomide, e... lenalidomide, e... | 18 Years - 80 Years | UMC Utrecht | |
| Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I | NCT00671801 | Malignant Gliom... | Irinotecan Lenalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM) | NCT00091624 | Multiple Myelom... | CC-5013 | 18 Years - | Celgene Corporation | |
| Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | NCT00179725 | Ovarian Cancer | CC-5013 liposomal doxor... | 18 Years - | Celgene | |
| Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma | NCT01555281 | Multiple Myelom... | Nelfinavir Lenalidomide Dexamethasone | 18 Years - | Swiss Group for Clinical Cancer Research | |
| A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma | NCT00413036 | Lymphoma, Non-H... | lenalidomide | 18 Years - | Celgene | |
| 5-Azacytidine With Lenalidomide in Patients With High Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | NCT01038635 | Leukemia | 5-Azacytidine Lenalidomide | - | M.D. Anderson Cancer Center | |
| Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma | NCT02155634 | Multiple Myelom... Neoplasms Plasma Cells Paraproteinemia... Blood Protein D... Hematologic Dis... Therapeutic Use... | Lenalidomide | 18 Years - | Celgene | |
| Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma | NCT00306813 | Relapse Refractory Mult... | Revlimid | 18 Years - | University of Wuerzburg | |
| Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma | NCT01484626 | Multiple Myelom... | Bendamustine | 18 Years - | Loyola University | |
| Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX) | NCT01183663 | Advanced Cancer... | Lenalidomide Bevacizumab Sorafenib Temsirolimus Lenalidomide Oxaliplatin Leucovorin 5-fluorouracil | 18 Years - | M.D. Anderson Cancer Center | |
| Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma | NCT00540644 | Multiple Myelom... | lenalidomide (R... Cyclophosphamid... Prednisone | 18 Years - | Indiana University | |
| Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL | NCT01703364 | CLL Chronic Lymphoc... | Lenalidomide | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) | NCT00628238 | Chronic Lymphoc... CLL Untreated Front-line First-Line Initial Therapy | Lenalidomide an... Lenalidomide an... | - | Chronic Lymphocytic Leukemia Research Consortium | |
| Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer | NCT00179699 | Non-Small Cell ... | CC-5013 pemetrexed | 18 Years - | Celgene | |
| Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease | NCT00632359 | Chronic Lymphoc... | Lenalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older | NCT00535873 | Leukemia CLL Chronic Lymphoc... Small Lymphocyt... | Lenalidomide | 65 Years - | M.D. Anderson Cancer Center | |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | NCT04739813 | Lymphoma Non-Hodgkin Lym... Diffuse Large B... Burkitt Lymphom... | obinutuzumab prednisone Revlimid Polatuzumab ibrutinib venetoclax | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma | NCT00778752 | Multiple Myelom... | Revlimid (Lenal... | 18 Years - | Universitätsklinikum Hamburg-Eppendorf | |
| UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma | NCT01621672 | Multiple Myelom... | Revlimid | 18 Years - | University of Arkansas | |
| Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma | NCT01729104 | Lymphoma | Carfilzomib Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Lenalidomide (Revlimid) for the Treatment of Refractory Cancer Pain | NCT00684242 | Advanced Cancer Pain | Lenalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma | NCT00689936 | Multiple Myelom... | Lenalidomide an... Lenalidomide pl... Melphalan, Pred... | 18 Years - | Celgene | |
| Lenalidomide and Paclitaxel in Prostate Cancer | NCT00933426 | Prostate Cancer | Lenalidomide Paclitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) | NCT00179660 | Non-Hodgkins Ly... | Lenalidomide | 18 Years - | Celgene | |
| Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma | NCT01380106 | Multiple Myelom... | Lenalidomide 15... Lenalidomide 25... | 18 Years - | Boston VA Research Institute, Inc. | |
| Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma | NCT00412581 | Melanoma | Lenalidomide Dacarbazine | 18 Years - | M.D. Anderson Cancer Center | |
| Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma | NCT01583283 | Multiple Myelom... | ACY-1215 lenalidomide Dexamethasone | 18 Years - | Celgene | |
| Maintenance Therapy Using Lenalidomide in Myeloma | NCT00430365 | Myeloma | lenalidomide placebo | 18 Years - 65 Years | University Hospital, Toulouse | |
| Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients | NCT03001804 | Multiple Myelom... | 18 Years - | Celgene | ||
| An Intensive Program With Quadruplet Induction and Consolidation Plus Tandem Autologous Stem Cell Transplantation in Newly Diagnosed High Risk Multiple Myeloma Patients | NCT03606577 | Multiple Myelom... | Carfilzomib Daratumumab Lenalidomide Dexamethasone | 18 Years - 65 Years | Nantes University Hospital | |
| Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | NCT00179712 | Ovarian Cancer | CC-5013 topotecan | 18 Years - | Celgene Corporation | |
| R2 in the Treatment of Follicular Lymphoma | NCT03715309 | Follicular Lymp... | Revlimid | 16 Years - 75 Years | Ruijin Hospital | |
| Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma | NCT00847639 | Multiple Myelom... | lenalidomide | 18 Years - 70 Years | Center for International Blood and Marrow Transplant Research | |
| A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial | NCT00737529 | Mantle Cell Lym... | lenalidomide | 18 Years - | Celgene | |
| Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease | NCT00632359 | Chronic Lymphoc... | Lenalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients | NCT02354313 | MANTLE CELL LYM... | Lenalidomide | 18 Years - 60 Years | Fondazione Italiana Linfomi - ETS | |
| A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia | NCT02538965 | Leukemia, Myelo... | Lenalidomide | 1 Year - 18 Years | Celgene | |
| A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. | NCT00405756 | Newly Diagnosed... | Lenalidomide: D... Melphalan Prednisone Aspirin Placebo Lenalidomide: D... Lenalidomide: O... | 65 Years - | Celgene Corporation | |
| Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone | NCT01237249 | Multiple Myelom... | Melphalan Prednisone Velcade Revlimid Dexamethasone | 65 Years - | PETHEMA Foundation | |
| Lenalidomide in Patients With Chronic Myelomonocytic Leukemia | NCT01368757 | Chronic Myelomo... | Revlimid | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas | NCT00837031 | Metastatic Panc... | Lenalidomide Gemcitabine | 18 Years - | SCRI Development Innovations, LLC | |
| Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT) | NCT01927718 | Myeloma | Thalidomide Lenalidomide Questionnaires | 18 Years - | M.D. Anderson Cancer Center | |
| Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality | NCT00065156 | Myelodysplastic... | lenalidomide | 18 Years - | Celgene | |
| A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma | NCT00622336 | Multiple Myelom... | CC-5013 Lenalidomide | 18 Years - | Celgene | |
| A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma | NCT00622336 | Multiple Myelom... | CC-5013 Lenalidomide | 18 Years - | Celgene | |
| Evaluation of the Immune Restoration Potential Of Lenalidomide | NCT02371577 | Chronic Lymphoc... | Lenalidomide | 18 Years - | University of California, San Diego | |
| Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma | NCT00179673 | Non-Hodgkins Ly... | Lenalidomide | 18 Years - | Celgene | |
| Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer | NCT01202890 | Ovarian Cancer Epithelial Ovar... Fallopian Tube ... Primary Periton... | Lenalidomide, L... Revlimid, Doxil... | - | New Mexico Cancer Care Alliance | |
| Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma | NCT01729104 | Lymphoma | Carfilzomib Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients | NCT00957385 | Acute Myeloid L... | Revlimid | 18 Years - | University Health Network, Toronto | |
| Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma | NCT00179725 | Ovarian Cancer | CC-5013 liposomal doxor... | 18 Years - | Celgene | |
| Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma | NCT00847639 | Multiple Myelom... | lenalidomide | 18 Years - 70 Years | Center for International Blood and Marrow Transplant Research |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
